

5

ABSTRACT OF THE DISCLOSURE

This invention provides pharmaceutically active enantiomers of the  
venlafaxine metabolite O-Desmethyl venlafaxine, R(-)-4-[2-(Dimethylamino)-1-(1-  
10 hydroxycyclo-hexyl)ethyl]phenol or R(-)-1-[2-(dimethylamino)-1-(4-  
hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-  
hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-  
hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or  
salt hydrates thereof, as well as pharmaceutical compositions utilizing these  
15 enantiomers and methods of using the enantiomers to treat, inhibit or control central  
nervous system disorders.